{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "EUR", "marketState": "REGULAR", "regularMarketChangePercent": -2.0746965, "regularMarketPrice": 4.72, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -10.89, "sharesOutstanding": 18398400, "bookValue": 7.942, "fiftyDayAverage": 4.47778, "fiftyDayAverageChange": 0.24221992, "fiftyDayAverageChangePercent": 0.054093756, "twoHundredDayAverage": 2.36734, "twoHundredDayAverageChange": 2.3526597, "twoHundredDayAverageChangePercent": 0.9937988, "marketCap": 89199504, "priceToBook": 0.59430873, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "tradeable": false, "cryptoTradeable": false, "exchange": "STU", "shortName": "Orchard Therapeutics PLC (ADRs)", "longName": "Orchard Therapeutics plc", "messageBoardId": "finmb_334227332", "exchangeTimezoneName": "Europe/Berlin", "exchangeTimezoneShortName": "CEST", "gmtOffSetMilliseconds": 7200000, "market": "dr_market", "esgPopulated": false, "firstTradeDateMilliseconds": 1551682800000, "priceHint": 4, "regularMarketChange": -0.10000038, "regularMarketTime": 1683871245, "regularMarketDayHigh": 4.72, "regularMarketDayRange": "4.72 - 4.72", "regularMarketDayLow": 4.72, "regularMarketVolume": 0, "regularMarketPreviousClose": 4.82, "bid": 4.72, "ask": 5.25, "fullExchangeName": "Stuttgart", "financialCurrency": "USD", "regularMarketOpen": 4.72, "averageDailyVolume3Month": 3, "averageDailyVolume10Day": 0, "fiftyTwoWeekLowChange": 4.39, "fiftyTwoWeekLowChangePercent": 13.303029, "fiftyTwoWeekRange": "0.33 - 7.0", "fiftyTwoWeekHighChange": -2.2800002, "fiftyTwoWeekHighChangePercent": -0.32571432, "fiftyTwoWeekLow": 0.33, "fiftyTwoWeekHigh": 7.0, "earningsTimestamp": 1678109400, "earningsTimestampStart": 1678109400, "earningsTimestampEnd": 1678109400, "trailingAnnualDividendRate": 0.0, "symbol": "OT10.SG"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "245 Hammersmith Road", "city": "London", "zip": "W6 8PW", "country": "United Kingdom", "phone": "44 20 3 808 8286", "website": "https://www.orchard-tx.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Orchard Therapeutics plc, a gene therapy company, research, develops, and commercialize hematopoietic stem cell and gene therapies in the United Kingdom, Italy, France, and Germany. It offers OTL-200, an ex vivo autologous hematopoietic stem cell gene therapy for the treatment of patients with metachromatic leukodystrophy under the Libmeldy brand; and Strimvelis, a gammaretroviral vector-based gene therapy for the treatment of adenosine deaminase deficiency. The company's program for neurodegenerative disorders comprises clinical proof of concept-stage program, which includes OTL-203 for the treatment of mucopolysaccharidosis type I and OTL-201 for mucopolysaccharidosis type IIIA, or MPS-IIIA; and pre-clinical program, OTL-204 for the treatment of frontotemporal dementia with progranulin mutations. In addition, it develops program for immunological disorders consist of pre-clinical programs, which includes OTL-104 for Crohn's disease with mutations in the nucleotide-binding oligomerization domain-containing protein 2; and OTL-105 for the treatment of hereditary angioedema. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.", "fullTimeEmployees": 166, "companyOfficers": [{"maxAge": 1, "name": "Dr. Bobby  Gaspar M.D., Ph.D.", "age": 58, "title": "CEO, Member of Scientific Advisory Board & Exec. Director", "yearBorn": 1964, "fiscalYear": 2021, "totalPay": {"raw": 850185, "fmt": "850.18k", "longFmt": "850,185"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Frank E. Thomas", "age": 52, "title": "Pres & COO", "yearBorn": 1970, "fiscalYear": 2021, "totalPay": {"raw": 716600, "fmt": "716.6k", "longFmt": "716,600"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Nicoletta  Loggia Ph.D.", "title": "Chief Technical Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Fulvio  Mavilio Ph.D.", "title": "Chief Scientific Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Renee T. Leck", "title": "Director of Investor Relations", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Benjamin  Navon", "title": "Director of Corp. Communications", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. John  Cerio", "title": "Chief Human Resource Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Robin  Kenselaar", "title": "Sr. VP & GM of EMEA Commercial Operations", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Braden  Parker", "title": "Chief Commercial Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Leslie  Meltzer Ph.D.", "title": "Chief Medical Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "compensationAsOfEpochDate": 1640908800, "maxAge": 86400}}], "error": null}}